The selective expression of the FGF21 co-receptor β-klotho in adipose, liver, and pancreas indicates a clear association with tissues involved in control of glucose and lipid metabolism, but does not impart which tissue modulates the specific effects of FGF21 pharmacology. The data presented here suggests that WAT has a significant role in eliciting the anti-diabetic (glucose and insulin lowering) efficacy of FGF21, and exogenous leptin can potentiate FGF21’s actions.
